Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP487 | DOI: 10.1530/endoabs.81.EP487

1Institute of Biophisics and Biochemistry at the NUUz, Metabolomics, Tashkent, Uzbekistan; 2Republican Specialised Scientific Practical Medical Centre of Hematology, Tashkent, Uzbekistan; 3Institute of Biophisics and Biochemistry at the NUUz, Tashkent, Uzbekistan; 4Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan


Background: In Pathogenesis of Neurodegeneration in Diabetes Mellitus (DM) addition to insulin resistance, glycemic control and blood plasma lipid levels existing other mechanisms were proposed. We investigated plasma insulin level in patients according to severity of diabetic neuropathy.

Materials and methods: In 32 people with DM2 glycemia, HbA1c, blood plasma insulin, blood total cholesterol, triglycerides, Low Density Lipoproteins (LDLP) levels were measured and compared regarding to DN severity by stages in DN1 and DN2 groups.

Results: People with DN1 and DN2 have the same age and disease duration. Glycemia and HbA1c level were also comparable between groups. Although, body weight and BMI (in 1.32 times), blood total cholesterol (in 1.3 times), triglycerides (in 1.32 times), LDLP (in 1.4 times) levels were significantly higher in DN2 group than DN1, blood plasma insulin was higher in DN2 group and suggested about involvement of insulin resistance into pathogenesis of DN. However, people in DN2 group used metformin with combination of sulfonilureas, whereas DN1 group mostly used metformin for lowering blood sugar.

Conclusion: DM2 patients with severe DN have higher BMI, blood lipids and plasma insulin level. Plasma insulin level have a linkage with DN severity in DM2 and play a role in the development of neurodegeneration.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.